TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy (ADT) Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior ADT
Brief Summary: The purpose of this study is to determine whether a reduced dose of aripiprazole is effective in treating patients with major depressive disorder


Options:
A: Arm Label: Vilazodone 10mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 20mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 40mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone 10mg, Vilazodone 20mg, Vilazodone 40mg
B: Arm Label: Early Intervention; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine Hydrochloride, Drug: Escitalopram | Arm Label: Delayed Intervention; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine Hydrochloride, Drug: Escitalopram | Intervention Type: DRUG; Name: Duloxetine Hydrochloride; Assigned to Arm(s): Delayed Intervention, Early Intervention | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Delayed Intervention, Early Intervention
C: Arm Label: Drug 2mg/Drug 5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 5mg, Drug: Aripiprazole 2mg | Arm Label: Placebo/Drug 2mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 2mg, Drug: Placebo | Arm Label: Placebo/Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole 5mg; Assigned to Arm(s): Drug 2mg/Drug 5mg | Intervention Type: DRUG; Name: Aripiprazole 2mg; Assigned to Arm(s): Drug 2mg/Drug 5mg, Placebo/Drug 2mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Drug 2mg, Placebo/Placebo
D: Arm Label: Add-on Quetiapine XR+SSRI/Venlafaxine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine XR, Drug: SSRI/Venlafaxine | Arm Label: Add-on Lithium+SSRI/Venlafaxine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium carbonate, Drug: SSRI/Venlafaxine | Arm Label: Monotherapy Quetiapine XR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine XR | Intervention Type: DRUG; Name: Quetiapine XR; Assigned to Arm(s): Add-on Quetiapine XR+SSRI/Venlafaxine, Monotherapy Quetiapine XR | Intervention Type: DRUG; Name: Lithium carbonate; Assigned to Arm(s): Add-on Lithium+SSRI/Venlafaxine | Intervention Type: DRUG; Name: SSRI/Venlafaxine; Assigned to Arm(s): Add-on Lithium+SSRI/Venlafaxine, Add-on Quetiapine XR+SSRI/Venlafaxine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transplantation in Myocardial Infarction Evaluation (TIME) Protocol: A Phase II, Randomized, Controlled, Double-Blind Trial Evaluating the Effect of Timing on the Administration of Bone Marrow Mononuclear Cells (BMMNCs) Versus Placebo in Patients With Acute Myocardial Infarction
Brief Summary: Heart attacks are a leading cause of death for both men and women in the United States. A heart attack occurs when blood flow to the heart is restricted, commonly due to a blood clot that has formed in one of the coronary arteries. If the clot becomes large enough, blood flow to the heart can be blocked almost completely and the heart muscle in that area can suffer permanent injury or death. Although a percutaneous coronary intervention (PCI) can be used to open up the blocked artery and restore blood flow to the heart muscle, there may be a significant amount of heart tissue that has been irreversibly damaged. Recent studies have shown that adult stem cells from bone marrow may be able to improve heart function after a heart attack. This study will evaluate the safety and effectiveness of using adult stem cells for improving heart function in people who have had a recent heart attack and a PCI.


Options:
A: Intervention Type: PROCEDURE; Name: cd133+cell intracoronary administration; Assigned to Arm(s): N/A
B: Arm Label: BMC; Type: EXPERIMENTAL; Interventions: Biological: Intracoronary infusion of enriched bone marrow-derived progenitor cells | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo medium supplemented with autologous serum | Intervention Type: BIOLOGICAL; Name: Intracoronary infusion of enriched bone marrow-derived progenitor cells; Assigned to Arm(s): BMC | Intervention Type: BIOLOGICAL; Name: Placebo medium supplemented with autologous serum; Assigned to Arm(s): Placebo
C: Arm Label: Myocardial infarction; Type: N/A; Interventions: Other: cell therapy | Arm Label: Ischemic cardiomyopathy; Type: N/A; Interventions: Other: cell therapy | Intervention Type: OTHER; Name: cell therapy; Assigned to Arm(s): Ischemic cardiomyopathy, Myocardial infarction
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adult stem cells | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adult stem cells | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Adult stem cells; Assigned to Arm(s): 1, 2 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 3, 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction
Brief Summary: More than 1 million Americans suffer heart attacks each year. Although current treatments are able to stabilize the condition of the heart, none is able to restore heart function as it was prior to the heart attack. Adult stem cells, which are immature cells that can become many different types of cells, may offer a potential means of reversing or preventing permanent damage caused by a heart attack. Recent studies have shown promise in using adult stem cells from bone marrow to reverse damage to the heart muscle caused by a heart attack, but more research is needed to assess the safety and effectiveness of stem cell use and to discover the best time to administer treatment. This study will evaluate the safety and effectiveness of using adult stem cell infusions 2 to 3 weeks after a heart attack for improving heart function in people who have had a recent heart attack and a common procedure called a percutaneous coronary intervention (PCI).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Adult stem cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Adult stem cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: The treatment group; Type: EXPERIMENTAL; Interventions: Procedure: Intracoronary injection of autologous bone marrow mononuclear cells | Arm Label: the control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Intracoronary injection of autologous bone marrow mononuclear cells; Assigned to Arm(s): The treatment group
C: Arm Label: Mesenchymal stem cell treatment group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesenchymal stem cell | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Control group | Intervention Type: DRUG; Name: Mesenchymal stem cell; Assigned to Arm(s): Mesenchymal stem cell treatment group | Intervention Type: DRUG; Name: Control group; Assigned to Arm(s): Control group
D: Intervention Type: PROCEDURE; Name: intracoronary injection of bone marrow cells; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Sine Waveform High Frequency Chest Wall Oscillation Using Different Settings in Cystic Fibrosis
Brief Summary: Our primary hypothesis is that airway clearance therapy with sine waveform HFCWO using higher inflation pressures combined with both low and high oscillator frequencies will result in greater sputum production compared to sine waveform HFCWO with lower inflation pressures and mid-frequency oscillations.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Other: Positive Expiratory Pressure (PEP) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System | Intervention Type: OTHER; Name: Positive Expiratory Pressure (PEP); Assigned to Arm(s): A | Intervention Type: OTHER; Name: High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System; Assigned to Arm(s): B
B: Arm Label: HFCWO Arm; Type: EXPERIMENTAL; Interventions: Device: Airway clearance Device | Arm Label: CPT Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Airway clearance Device; Assigned to Arm(s): HFCWO Arm
C: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation
D: Arm Label: HFCWC with higher pressure/variable frequency settings; Type: ACTIVE_COMPARATOR; Interventions: Device: HFCWC with higher pressure/variable-frequency settings, Device: HFCWC with lower pressure/mid-frequency settings | Arm Label: HFCWC with lower pressure/mid-frequency settings; Type: ACTIVE_COMPARATOR; Interventions: Device: HFCWC with higher pressure/variable-frequency settings, Device: HFCWC with lower pressure/mid-frequency settings | Intervention Type: DEVICE; Name: HFCWC with higher pressure/variable-frequency settings; Assigned to Arm(s): HFCWC with higher pressure/variable frequency settings, HFCWC with lower pressure/mid-frequency settings | Intervention Type: DEVICE; Name: HFCWC with lower pressure/mid-frequency settings; Assigned to Arm(s): HFCWC with higher pressure/variable frequency settings, HFCWC with lower pressure/mid-frequency settings

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Sine Waveform High Frequency Chest Wall Oscillation Using Different Settings in Cystic Fibrosis
Brief Summary: Our primary hypothesis is that airway clearance therapy with sine waveform HFCWO using higher inflation pressures combined with both low and high oscillator frequencies will result in greater sputum production compared to sine waveform HFCWO with lower inflation pressures and mid-frequency oscillations.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Other: Positive Expiratory Pressure (PEP) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System | Intervention Type: OTHER; Name: Positive Expiratory Pressure (PEP); Assigned to Arm(s): A | Intervention Type: OTHER; Name: High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System; Assigned to Arm(s): B
B: Arm Label: HFCWC with higher pressure/variable frequency settings; Type: ACTIVE_COMPARATOR; Interventions: Device: HFCWC with higher pressure/variable-frequency settings, Device: HFCWC with lower pressure/mid-frequency settings | Arm Label: HFCWC with lower pressure/mid-frequency settings; Type: ACTIVE_COMPARATOR; Interventions: Device: HFCWC with higher pressure/variable-frequency settings, Device: HFCWC with lower pressure/mid-frequency settings | Intervention Type: DEVICE; Name: HFCWC with higher pressure/variable-frequency settings; Assigned to Arm(s): HFCWC with higher pressure/variable frequency settings, HFCWC with lower pressure/mid-frequency settings | Intervention Type: DEVICE; Name: HFCWC with lower pressure/mid-frequency settings; Assigned to Arm(s): HFCWC with higher pressure/variable frequency settings, HFCWC with lower pressure/mid-frequency settings
C: Intervention Type: DEVICE; Name: High frequency chest wall oscillator; Assigned to Arm(s): N/A
D: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Sine Waveform High Frequency Chest Wall Oscillation Using Different Settings in Cystic Fibrosis
Brief Summary: Our primary hypothesis is that airway clearance therapy with sine waveform HFCWO using higher inflation pressures combined with both low and high oscillator frequencies will result in greater sputum production compared to sine waveform HFCWO with lower inflation pressures and mid-frequency oscillations.


Options:
A: Arm Label: HFCWC with higher pressure/variable frequency settings; Type: ACTIVE_COMPARATOR; Interventions: Device: HFCWC with higher pressure/variable-frequency settings, Device: HFCWC with lower pressure/mid-frequency settings | Arm Label: HFCWC with lower pressure/mid-frequency settings; Type: ACTIVE_COMPARATOR; Interventions: Device: HFCWC with higher pressure/variable-frequency settings, Device: HFCWC with lower pressure/mid-frequency settings | Intervention Type: DEVICE; Name: HFCWC with higher pressure/variable-frequency settings; Assigned to Arm(s): HFCWC with higher pressure/variable frequency settings, HFCWC with lower pressure/mid-frequency settings | Intervention Type: DEVICE; Name: HFCWC with lower pressure/mid-frequency settings; Assigned to Arm(s): HFCWC with higher pressure/variable frequency settings, HFCWC with lower pressure/mid-frequency settings
B: Arm Label: Chest Physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: Chest Physiotherapy + Exercise Program; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy + Exercise Program | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest Physiotherapy + Exercise Program; Assigned to Arm(s): Chest Physiotherapy + Exercise Program
C: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: OTHER; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Cadaver Donor Renal Transplantation: A Study to Evaluate the Avoidance of Long-Term Nephrotoxic Calcineurin Inhibitor Therapy
Brief Summary: To compare in a randomized prospective study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy vs. our conventional therapy in recipients of first cadaver (CAD) kidneys.


Options:
A: Arm Label: Mycophenolate sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus | Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus | Intervention Type: DRUG; Name: Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus; Assigned to Arm(s): Mycophenolate sodium
B: Arm Label: EVR+rCNI; Type: EXPERIMENTAL; Interventions: Biological: Induction therapy, Drug: Corticosteroids, Drug: EVR+rCNI | Arm Label: MPA+sCNI; Type: ACTIVE_COMPARATOR; Interventions: Biological: Induction therapy, Drug: Corticosteroids, Drug: MPA+sCNI | Intervention Type: BIOLOGICAL; Name: Induction therapy; Assigned to Arm(s): EVR+rCNI, MPA+sCNI | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): EVR+rCNI, MPA+sCNI | Intervention Type: DRUG; Name: EVR+rCNI; Assigned to Arm(s): EVR+rCNI | Intervention Type: DRUG; Name: MPA+sCNI; Assigned to Arm(s): MPA+sCNI
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Thymoglobulin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Campath-1H | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Daclizumab | Intervention Type: DRUG; Name: Thymoglobulin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Campath-1H; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): C
D: Intervention Type: DRUG; Name: daclizumab; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Trial of Topiramate for Cocaine Addiction
Brief Summary: This is an outpatient clinical trial of topiramate for addressing cocaine dependence and reduction of cocaine associated behaviors in opiate dependent drug users maintained on methadone treatment.

The study aims to answer whether topiramate

1. is safe and acceptable to methadone patients
2. reduces cocaine use
3. helps with collateral problems such as alcohol abuse, tobacco dependence, anxiety, PTSD and/or pain symptoms. The study will also evaluate topiramate effect on neuro-cognitive performance.


Options:
A: Arm Label: 1 topiramate + CR; Type: EXPERIMENTAL; Interventions: Drug: topiramate, Behavioral: Contingency Reinforcement | Arm Label: 2 topiramate + NonCR; Type: EXPERIMENTAL; Interventions: Drug: topiramate | Arm Label: 4 Placebo + NonCR; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo + NonCR | Arm Label: 3 Placebo + CR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Reinforcement | Intervention Type: DRUG; Name: topiramate; Assigned to Arm(s): 1 topiramate + CR, 2 topiramate + NonCR | Intervention Type: BEHAVIORAL; Name: Contingency Reinforcement; Assigned to Arm(s): 1 topiramate + CR, 3 Placebo + CR | Intervention Type: DRUG; Name: placebo + NonCR; Assigned to Arm(s): 4 Placebo + NonCR
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vigabatrin, Behavioral: Group therapy | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Group therapy | Intervention Type: DRUG; Name: Vigabatrin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B | Intervention Type: BEHAVIORAL; Name: Group therapy; Assigned to Arm(s): A, B
C: Arm Label: Lithium plus Divalproex; Type: EXPERIMENTAL; Interventions: Drug: Lithium, Drug: Divalproex | Arm Label: Lithium plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lithium, Drug: Placebo | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): Lithium plus Divalproex, Lithium plus placebo | Intervention Type: DRUG; Name: Divalproex; Assigned to Arm(s): Lithium plus Divalproex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Lithium plus placebo
D: Arm Label: Topiramate; Type: EXPERIMENTAL; Interventions: Drug: Topiramate + Cognitive Behavioral Therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Cognitive Behavioral Therapy | Intervention Type: DRUG; Name: Topiramate + Cognitive Behavioral Therapy; Assigned to Arm(s): Topiramate | Intervention Type: DRUG; Name: Placebo + Cognitive Behavioral Therapy; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tension-free Vaginal Tape Management of Stress Incontinence in Women: Randomized Trial of TVT Secur Versus TVT
Brief Summary: This randomized multi-centre trial will recruit women with stress urinary incontinence who need surgical treatment for their condition. 300 women will be allocated either to receive a TVT Secur or a standard TVT surgical procedure. The main outcome is effectiveness of the procedure, determined using a 1-hour pad test (which tests for urine leakage) 12 months after surgery. The study will be carried out in 4 to 6 centers and will involve urogynaecologists, urologists and general obstetrician-gynaecologists: all clinicians will have received adequate training.


Options:
A: Arm Label: SIS single incision sling; Type: EXPERIMENTAL; Interventions: Device: SIS - Innovative fixation single incision sling | Arm Label: TOT trans obturator tape/sling; Type: ACTIVE_COMPARATOR; Interventions: Device: TOT - inside-out trans-obturator tape/sling | Intervention Type: DEVICE; Name: TOT - inside-out trans-obturator tape/sling; Assigned to Arm(s): TOT trans obturator tape/sling | Intervention Type: DEVICE; Name: SIS - Innovative fixation single incision sling; Assigned to Arm(s): SIS single incision sling
B: Arm Label: Ajust sling; Type: EXPERIMENTAL; Interventions: Procedure: Ajust system, Procedure: TVT/TVT-O | Arm Label: TVT/TVT-O, polypropylne slings; Type: EXPERIMENTAL; Interventions: Procedure: Ajust system, Procedure: TVT/TVT-O | Intervention Type: PROCEDURE; Name: Ajust system; Assigned to Arm(s): Ajust sling, TVT/TVT-O, polypropylne slings | Intervention Type: PROCEDURE; Name: TVT/TVT-O; Assigned to Arm(s): Ajust sling, TVT/TVT-O, polypropylne slings
C: Arm Label: Ajust; Type: EXPERIMENTAL; Interventions: Device: Ajust sling | Arm Label: Classical transobturator tape; Type: ACTIVE_COMPARATOR; Interventions: Device: Classical transobturator sling | Intervention Type: DEVICE; Name: Ajust sling; Assigned to Arm(s): Ajust | Intervention Type: DEVICE; Name: Classical transobturator sling; Assigned to Arm(s): Classical transobturator tape
D: Arm Label: TVT Secur surgical device; Type: EXPERIMENTAL; Interventions: Procedure: TVT Secur (Gynecare) | Arm Label: TVT surgical device; Type: ACTIVE_COMPARATOR; Interventions: Procedure: TVT (Gynecare) | Intervention Type: PROCEDURE; Name: TVT Secur (Gynecare); Assigned to Arm(s): TVT Secur surgical device | Intervention Type: PROCEDURE; Name: TVT (Gynecare); Assigned to Arm(s): TVT surgical device

Answer: D